Urine drug testing in chronic pain

Paul J. Christo, Laxmaiah Manchikanti, Xiulu Ruan, Michael Bottros, Hans Hansen, Daneshvari R. Solanki, Arthur E. Jordan, James Colson

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

Therapeutic use, overuse, abuse, and diversion of controlled substances in managing chronic non-cancer pain continue to be an issue for physicians and patients. The challenge is to eliminate or significantly curtail abuse of controlled prescription drugs while still assuring the proper treatment of those patients. Some physicians are apprehensive regarding the use of chronic opioid therapy in chronic non-cancer pain due to a perceived lack of proven evidence, the misuse of opioids, tolerance, dependence, and hyperalgesia. However, others have criticized the underuse of opioids, resulting in the undertreatment of pain. It has been the convention that federal, state, and local governments; professional associations; as well as pharmaceutical companies, physicians, accrediting bodies, medical licensure boards, and the public all share responsibility for preventing abuse of controlled prescription drugs. To overcome the critical challenge of eliminating or significantly curtailing abuse of controlled prescription drugs and at the same time assuring the appropriate treatment for those patients who can be helped by these medications, it is crucial to practice adherence or compliance monitoring of opioid therapy. Compliance monitoring has been shown to be crucial in delivering proper opioid therapy and preserving this therapy for the future. Urine drug testing (UDT) is considered one of the mainstays of adherence monitoring in conjunction with prescription monitoring programs and other screening tools, however, UDT is associated with multiple limitations secondary to potential pitfalls related to drug metabolism, reliability of the tests, and the knowledge of the pain physician. UDT is a widely available and familiar method for monitoring opioid use in chronic pain patients. UDT can provide tools for tracking patient compliance and expose possible drug misuse and abuse. UDT is one of the major tools of adherence monitoring in the assessment of the patient's predisposition to, and patterns of, drug misuse/abuse - a vital first step towards establishing and maintaining the safe and effective use of opioid analgesics in the treatment of chronic pain. This comprehensive review provides the role of UDT in monitoring chronic opioid therapy along with reliability and accuracy, appropriate use, overuse, misuse, and abuse.

Original languageEnglish (US)
Pages (from-to)123-143
Number of pages21
JournalPain Physician
Volume14
Issue number2
StatePublished - Mar 2011
Externally publishedYes

Fingerprint

Chronic Pain
Opioid Analgesics
Urine
Prescription Drug Misuse
Pharmaceutical Preparations
Pain
Therapeutics
Physicians
Prescription Drug Diversion
Compliance
Substance-Related Disorders
Medical Licensure
Occupational Health Physicians
State Government
Local Government
Federal Government
Hyperalgesia
Therapeutic Uses
Patient Compliance
Prescriptions

Keywords

  • Abuse
  • Adherence monitoring
  • Benzodiazepines
  • Chromatography
  • Compliance monitoring
  • Controlled substances
  • Diversion
  • False-negatives
  • False-positives
  • Illicit drugs
  • Immunoassay
  • Opioids
  • Prescription monitoring programs
  • Urine drug testing

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Christo, P. J., Manchikanti, L., Ruan, X., Bottros, M., Hansen, H., Solanki, D. R., ... Colson, J. (2011). Urine drug testing in chronic pain. Pain Physician, 14(2), 123-143.

Urine drug testing in chronic pain. / Christo, Paul J.; Manchikanti, Laxmaiah; Ruan, Xiulu; Bottros, Michael; Hansen, Hans; Solanki, Daneshvari R.; Jordan, Arthur E.; Colson, James.

In: Pain Physician, Vol. 14, No. 2, 03.2011, p. 123-143.

Research output: Contribution to journalArticle

Christo, PJ, Manchikanti, L, Ruan, X, Bottros, M, Hansen, H, Solanki, DR, Jordan, AE & Colson, J 2011, 'Urine drug testing in chronic pain', Pain Physician, vol. 14, no. 2, pp. 123-143.
Christo PJ, Manchikanti L, Ruan X, Bottros M, Hansen H, Solanki DR et al. Urine drug testing in chronic pain. Pain Physician. 2011 Mar;14(2):123-143.
Christo, Paul J. ; Manchikanti, Laxmaiah ; Ruan, Xiulu ; Bottros, Michael ; Hansen, Hans ; Solanki, Daneshvari R. ; Jordan, Arthur E. ; Colson, James. / Urine drug testing in chronic pain. In: Pain Physician. 2011 ; Vol. 14, No. 2. pp. 123-143.
@article{9efbe77ab8fd488a9a9210dff18727c3,
title = "Urine drug testing in chronic pain",
abstract = "Therapeutic use, overuse, abuse, and diversion of controlled substances in managing chronic non-cancer pain continue to be an issue for physicians and patients. The challenge is to eliminate or significantly curtail abuse of controlled prescription drugs while still assuring the proper treatment of those patients. Some physicians are apprehensive regarding the use of chronic opioid therapy in chronic non-cancer pain due to a perceived lack of proven evidence, the misuse of opioids, tolerance, dependence, and hyperalgesia. However, others have criticized the underuse of opioids, resulting in the undertreatment of pain. It has been the convention that federal, state, and local governments; professional associations; as well as pharmaceutical companies, physicians, accrediting bodies, medical licensure boards, and the public all share responsibility for preventing abuse of controlled prescription drugs. To overcome the critical challenge of eliminating or significantly curtailing abuse of controlled prescription drugs and at the same time assuring the appropriate treatment for those patients who can be helped by these medications, it is crucial to practice adherence or compliance monitoring of opioid therapy. Compliance monitoring has been shown to be crucial in delivering proper opioid therapy and preserving this therapy for the future. Urine drug testing (UDT) is considered one of the mainstays of adherence monitoring in conjunction with prescription monitoring programs and other screening tools, however, UDT is associated with multiple limitations secondary to potential pitfalls related to drug metabolism, reliability of the tests, and the knowledge of the pain physician. UDT is a widely available and familiar method for monitoring opioid use in chronic pain patients. UDT can provide tools for tracking patient compliance and expose possible drug misuse and abuse. UDT is one of the major tools of adherence monitoring in the assessment of the patient's predisposition to, and patterns of, drug misuse/abuse - a vital first step towards establishing and maintaining the safe and effective use of opioid analgesics in the treatment of chronic pain. This comprehensive review provides the role of UDT in monitoring chronic opioid therapy along with reliability and accuracy, appropriate use, overuse, misuse, and abuse.",
keywords = "Abuse, Adherence monitoring, Benzodiazepines, Chromatography, Compliance monitoring, Controlled substances, Diversion, False-negatives, False-positives, Illicit drugs, Immunoassay, Opioids, Prescription monitoring programs, Urine drug testing",
author = "Christo, {Paul J.} and Laxmaiah Manchikanti and Xiulu Ruan and Michael Bottros and Hans Hansen and Solanki, {Daneshvari R.} and Jordan, {Arthur E.} and James Colson",
year = "2011",
month = "3",
language = "English (US)",
volume = "14",
pages = "123--143",
journal = "Pain Physician",
issn = "1533-3159",
publisher = "Association of Pain Management Anesthesiologists",
number = "2",

}

TY - JOUR

T1 - Urine drug testing in chronic pain

AU - Christo, Paul J.

AU - Manchikanti, Laxmaiah

AU - Ruan, Xiulu

AU - Bottros, Michael

AU - Hansen, Hans

AU - Solanki, Daneshvari R.

AU - Jordan, Arthur E.

AU - Colson, James

PY - 2011/3

Y1 - 2011/3

N2 - Therapeutic use, overuse, abuse, and diversion of controlled substances in managing chronic non-cancer pain continue to be an issue for physicians and patients. The challenge is to eliminate or significantly curtail abuse of controlled prescription drugs while still assuring the proper treatment of those patients. Some physicians are apprehensive regarding the use of chronic opioid therapy in chronic non-cancer pain due to a perceived lack of proven evidence, the misuse of opioids, tolerance, dependence, and hyperalgesia. However, others have criticized the underuse of opioids, resulting in the undertreatment of pain. It has been the convention that federal, state, and local governments; professional associations; as well as pharmaceutical companies, physicians, accrediting bodies, medical licensure boards, and the public all share responsibility for preventing abuse of controlled prescription drugs. To overcome the critical challenge of eliminating or significantly curtailing abuse of controlled prescription drugs and at the same time assuring the appropriate treatment for those patients who can be helped by these medications, it is crucial to practice adherence or compliance monitoring of opioid therapy. Compliance monitoring has been shown to be crucial in delivering proper opioid therapy and preserving this therapy for the future. Urine drug testing (UDT) is considered one of the mainstays of adherence monitoring in conjunction with prescription monitoring programs and other screening tools, however, UDT is associated with multiple limitations secondary to potential pitfalls related to drug metabolism, reliability of the tests, and the knowledge of the pain physician. UDT is a widely available and familiar method for monitoring opioid use in chronic pain patients. UDT can provide tools for tracking patient compliance and expose possible drug misuse and abuse. UDT is one of the major tools of adherence monitoring in the assessment of the patient's predisposition to, and patterns of, drug misuse/abuse - a vital first step towards establishing and maintaining the safe and effective use of opioid analgesics in the treatment of chronic pain. This comprehensive review provides the role of UDT in monitoring chronic opioid therapy along with reliability and accuracy, appropriate use, overuse, misuse, and abuse.

AB - Therapeutic use, overuse, abuse, and diversion of controlled substances in managing chronic non-cancer pain continue to be an issue for physicians and patients. The challenge is to eliminate or significantly curtail abuse of controlled prescription drugs while still assuring the proper treatment of those patients. Some physicians are apprehensive regarding the use of chronic opioid therapy in chronic non-cancer pain due to a perceived lack of proven evidence, the misuse of opioids, tolerance, dependence, and hyperalgesia. However, others have criticized the underuse of opioids, resulting in the undertreatment of pain. It has been the convention that federal, state, and local governments; professional associations; as well as pharmaceutical companies, physicians, accrediting bodies, medical licensure boards, and the public all share responsibility for preventing abuse of controlled prescription drugs. To overcome the critical challenge of eliminating or significantly curtailing abuse of controlled prescription drugs and at the same time assuring the appropriate treatment for those patients who can be helped by these medications, it is crucial to practice adherence or compliance monitoring of opioid therapy. Compliance monitoring has been shown to be crucial in delivering proper opioid therapy and preserving this therapy for the future. Urine drug testing (UDT) is considered one of the mainstays of adherence monitoring in conjunction with prescription monitoring programs and other screening tools, however, UDT is associated with multiple limitations secondary to potential pitfalls related to drug metabolism, reliability of the tests, and the knowledge of the pain physician. UDT is a widely available and familiar method for monitoring opioid use in chronic pain patients. UDT can provide tools for tracking patient compliance and expose possible drug misuse and abuse. UDT is one of the major tools of adherence monitoring in the assessment of the patient's predisposition to, and patterns of, drug misuse/abuse - a vital first step towards establishing and maintaining the safe and effective use of opioid analgesics in the treatment of chronic pain. This comprehensive review provides the role of UDT in monitoring chronic opioid therapy along with reliability and accuracy, appropriate use, overuse, misuse, and abuse.

KW - Abuse

KW - Adherence monitoring

KW - Benzodiazepines

KW - Chromatography

KW - Compliance monitoring

KW - Controlled substances

KW - Diversion

KW - False-negatives

KW - False-positives

KW - Illicit drugs

KW - Immunoassay

KW - Opioids

KW - Prescription monitoring programs

KW - Urine drug testing

UR - http://www.scopus.com/inward/record.url?scp=79952827513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952827513&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 123

EP - 143

JO - Pain Physician

JF - Pain Physician

SN - 1533-3159

IS - 2

ER -